1
|
Balinandi S, Whitmer S, Mulei S, Nassuna C, Pimundu G, Muyigi T, Kainulainen M, Shedroff E, Krapiunaya I, Scholte F, Nyakarahuka L, Tumusiime A, Kyondo J, Baluku J, Kiconco J, Harris JR, Ario AR, Kagirita A, Bosa HK, Ssewanyana I, Nabadda S, Mwebesa HG, Aceng JR, Atwine D, Lutwama JJ, Shoemaker TR, Montgomery JM, Kaleebu P, Klena JD. Molecular characterization of the 2022 Sudan virus disease outbreak in Uganda. J Virol 2023; 97:e0059023. [PMID: 37750724 PMCID: PMC10617429 DOI: 10.1128/jvi.00590-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 08/08/2023] [Indexed: 09/27/2023] Open
Abstract
IMPORTANCE Ebola disease (EBOD) is a public health threat with a high case fatality rate. Most EBOD outbreaks have occurred in remote locations, but the 2013-2016 Western Africa outbreak demonstrated how devastating EBOD can be when it reaches an urban population. Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated. The Mubende variant exhibited 96% amino acid similarity with historic SUDV sequences from the 1970s and a high degree of conservation throughout the outbreak, which was important for ongoing diagnostics and highly promising for future therapy development. Genetic differences between viruses identified during the Mubende SVD outbreak were linked with epidemiological data to better interpret viral spread and contact tracing chains. This methodology should be used to better integrate discrete epidemiological and sequence data for future viral outbreaks.
Collapse
Affiliation(s)
| | - Shannon Whitmer
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Sophia Mulei
- Uganda Virus Research Institute, Entebbe, Uganda
| | | | - Godfrey Pimundu
- Uganda National Health Laboratory Services, Ministry of Health, Kampala, Uganda
| | - Tonny Muyigi
- Uganda National Health Laboratory Services, Ministry of Health, Kampala, Uganda
| | - Markus Kainulainen
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Elizabeth Shedroff
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Inna Krapiunaya
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Florine Scholte
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Luke Nyakarahuka
- Uganda Virus Research Institute, Entebbe, Uganda
- College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda
| | | | | | - Jimmy Baluku
- Uganda Virus Research Institute, Entebbe, Uganda
| | | | | | - Alex R. Ario
- Uganda Public Health Fellowship Program, Kampala, Uganda
| | | | - Henry K. Bosa
- Ministry of Health, Kampala, Uganda
- Kellogg College, University of Oxford, Oxford, United Kingdom
| | - Isaac Ssewanyana
- Uganda National Health Laboratory Services, Ministry of Health, Kampala, Uganda
| | - Susan Nabadda
- Uganda National Health Laboratory Services, Ministry of Health, Kampala, Uganda
| | | | | | | | | | - Trevor R. Shoemaker
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Joel M. Montgomery
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Pontiano Kaleebu
- Uganda Virus Research Institute, Entebbe, Uganda
- MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda
| | - John D. Klena
- Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
2
|
Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B, Spencer D, Bramble MS, McIlwan D, Kelly JD, Mukadi D, Kingebeni PM, Ahuka S, Okitolonda-Wemakoy E, Muyembe-Tamfum JJ, Rimoin AW. Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo. PLoS Negl Trop Dis 2021; 15:e0009566. [PMID: 34383755 PMCID: PMC8384205 DOI: 10.1371/journal.pntd.0009566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 08/24/2021] [Accepted: 06/15/2021] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Ebola virus (EBOV) is a zoonotic filovirus spread through exposure to infected bodily fluids of a human or animal. Though EBOV is capable of causing severe disease, referred to as Ebola Virus Disease (EVD), individuals who have never been diagnosed with confirmed, probable or suspected EVD can have detectable EBOV antigen-specific antibodies in their blood. This study aims to identify risk factors associated with detectable antibody levels in the absence of an EVD diagnosis. METHODOLOGY Data was collected from September 2015 to August 2017 from 1,366 consenting individuals across four study sites in the DRC (Boende, Kabondo-Dianda, Kikwit, and Yambuku). Seroreactivity was determined to EBOV GP IgG using Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA kits (Alpha Diagnostic International, Inc.) in Kinshasa, DRC; any result above 4.7 units/mL was considered seroreactive. Among the respondents, 113 (8.3%) were considered seroreactive. Several zoonotic exposures were associated with EBOV seroreactivity after controlling for age, sex, healthcare worker status, location, and history of contact with an EVD case, namely: ever having contact with bats, ever having contact with rodents, and ever eating non-human primate meat. Contact with monkeys or non-human primates was not associated with seroreactivity. CONCLUSIONS This analysis suggests that some zoonotic exposures that have been linked to EVD outbreaks can also be associated with EBOV GP seroreactivity in the absence of diagnosed EVD. Future investigations should seek to clarify the relationships between zoonotic exposures, seroreactivity, asymptomatic infection, and EVD.
Collapse
Affiliation(s)
- Anna Bratcher
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Nicole A. Hoff
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Reena H. Doshi
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Adva Gadoth
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Megan Halbrook
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Patrick Mukadi
- Institut National de Recherche Biomedicale, Kinshasa, DRC
| | - Kamy Musene
- Kinshasa School of Public Health, Kinshasa, DRC
| | - Benoit Ilunga-Kebela
- Direction de lutte contre la maladie-Ministère de la santé Publique, Kinshasa, DRC
| | - D’Andre Spencer
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| | - Matthew S. Bramble
- Center for Genetic Medicine Research, Children’s National Medical Center, Washington DC, United States of America
| | - David McIlwan
- Department of Microbiology and Immunology, Stanford University, Stanford, California, United States of America
| | - J. Daniel Kelly
- School of Medicine, University of California, San Francisco, San Francisco, California, United States of America
| | - Daniel Mukadi
- Institut National de Recherche Biomedicale, Kinshasa, DRC
| | | | - Steve Ahuka
- Institut National de Recherche Biomedicale, Kinshasa, DRC
| | | | | | - Anne W. Rimoin
- UCLA Fielding School of Public Health, Los Angeles, California, United States of America
| |
Collapse
|
3
|
Bane S, Rosenke K, Maiga O, Feldmann F, Meade-White K, Callison J, Safronetz D, Sogoba N, Feldmann H. Ebola Virus IgG Seroprevalence in Southern Mali. Emerg Infect Dis 2021; 27:1681-1684. [PMID: 34013879 PMCID: PMC8153881 DOI: 10.3201/eid2706.203510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Mali had 2 reported introductions of Ebola virus (EBOV) during the 2013–2016 West Africa epidemic. Previously, no evidence for EBOV circulation was reported in Mali. We performed an EBOV serosurvey study in southern Mali. We found low seroprevalence in the population, indicating local exposure to EBOV or closely related ebola viruses.
Collapse
|
4
|
Doshi RH, Hoff NA, Bratcher A, Mukadi P, Gadoth A, Nicholson BP, Williams R, Mukadi D, Mossoko M, Wasiswa J, Mwanza A, Sinai C, Alfonso VH, Shah R, Bramble MS, Ilunga-Kebela B, Okitolonda-Wemakoy E, Muyembe-Tamfum JJ, Rimoin AW. Risk factors for Ebola exposure in healthcare workers in Boende, Tshuapa Province, Democratic Republic of the Congo. J Infect Dis 2020; 226:608-615. [PMID: 33269402 PMCID: PMC9441197 DOI: 10.1093/infdis/jiaa747] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 11/30/2020] [Indexed: 02/06/2023] Open
Abstract
Healthcare workers (HCW) are more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people in the general population due to close physical contact with patients and potential exposure to infectious fluids. However, not all will fall ill. Despite evidence of subclinical and paucisymptomatic Ebola Virus Disease (EVD), the prevalence and associated risk factors remains unknown. We conducted a serosurvey among healthcare workers in the town of Boende in Tshuapa Province, Democratic Republic of Congo (DRC). Human anti-EBOV Glycoprotein (GP) IgG titers were measured using a commercially available ELISA kit. We assessed associations between anti-EBOV IgG seroreactivity, defined as ≥2.5 units/mL and risk factors using univariable and multivariable logistic regression. Sensitivity analyses explored a more conservative cutoff >5 units/mL. Overall, 22.5% of HCWs were seroreactive for EBOV. In multivariable analyses, using any form of personal protective equipment (PPE) when interacting with a confirmed, probable, or suspect EVD case was negatively associated with seroreactivity [0.23 (95% CI: 0.07, 0.73)]. Our results suggest high exposure to EBOV among HCWs and provide additional evidence for asymptomatic or minimally symptomatic EVD. Further studies should be conducted to determine the probability of onward transmission and if seroreactivity is associated with immunity.
Collapse
Affiliation(s)
- Reena H Doshi
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Nicole A Hoff
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Anna Bratcher
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Patrick Mukadi
- Institut National de Recherche Biomédicale, Kinshasa, DRC.,Faculté de Médecine, Université de Kinshasa, DRC
| | - Adva Gadoth
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | | | | | - Daniel Mukadi
- Institut National de Recherche Biomédicale, Kinshasa, DRC.,Faculté de Médecine, Université de Kinshasa, DRC
| | - Matthias Mossoko
- Direction de lutte contre la Maladie-Ministère de la Santé Publique, DRC
| | - Joseph Wasiswa
- UCLA-DRC Research Program, Kinshasa, DRC.,Direction de lutte contre la Maladie-Ministère de la Santé Publique, DRC
| | | | - Cyrus Sinai
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Vivian H Alfonso
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Rupal Shah
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| | - Matthew S Bramble
- Department of Genetic Medicine Research, Children's Research Institute, Children's National Medical Center, Washington, D.C. USA
| | | | | | | | - Anne W Rimoin
- Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA, USA
| |
Collapse
|
5
|
Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P, Weiss S, Hewson R, Punch EK, Barr JN, Witkowski PT, Couacy-Hymann E, Marzi A, Dorner BG, Kurth A. Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples. PLoS Negl Trop Dis 2020; 14:e0008699. [PMID: 33095766 PMCID: PMC7641473 DOI: 10.1371/journal.pntd.0008699] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 11/04/2020] [Accepted: 08/11/2020] [Indexed: 11/18/2022] Open
Abstract
Surveillance of highly pathogenic viruses circulating in both human and animal populations is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the burden of disease by serological assay could be used as an early warning system for imminent outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the multitude of highly pathogenic viruses necessitates the need to identify specific antibodies against several targets from both humans as well as from potential reservoir animals such as bats. In order to address this, we have developed a broadly reactive multiplex microsphere immunoassay (MMIA) for the detection of antibodies against several highly pathogenic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each respective NP was shown by testing sera from humans and non-human primates with known infection status. The usefulness of our assay for serosurveillance was shown by determining the immune response against the NP antigens in a panel of 129 human serum samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera from the German blood bank. We found good agreement between our MMIA and commercial or in-house reference methods by ELISA or IIFT with statistically significant higher binding to both EBOV NP and MARV NP coupled microspheres in the Guinea panel. Finally, the MMIA was successfully adapted to detect antibodies from bats that had been inoculated with EBOV- and MARV- virus-like particles, highlighting the versatility of this technique and potentially enabling the monitoring of wildlife as well as human populations with this assay. We were thus able to develop and validate a sensitive and broadly reactive high-throughput serological assay which could be used as a screening tool to detect antibodies against several highly pathogenic viruses.
Collapse
Affiliation(s)
- Rebecca Surtees
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Daniel Stern
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Katharina Ahrens
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Nicole Kromarek
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Angelika Lander
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Petra Kreher
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Sabrina Weiss
- Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | - Roger Hewson
- Virology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, United Kingdom
| | - Emma K Punch
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom
| | - John N Barr
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom
| | - Peter T Witkowski
- Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | | | - Andrea Marzi
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States of America
| | - Brigitte G Dorner
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Andreas Kurth
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
6
|
Couturier C, Wada A, Louis K, Mistretta M, Beitz B, Povogui M, Ripaux M, Mignon C, Werle B, Lugari A, Pannetier D, Godard S, Bocquin A, Mely S, Béavogui I, Hébélamou J, Leuenberger D, Leissner P, Yamamoto T, Lécine P, Védrine C, Chaix J. Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection. PLoS Negl Trop Dis 2020; 14:e0007965. [PMID: 31951615 PMCID: PMC6992227 DOI: 10.1371/journal.pntd.0007965] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 01/30/2020] [Accepted: 11/27/2019] [Indexed: 01/16/2023] Open
Abstract
Hemorrhagic fever outbreaks are difficult to diagnose and control in part because of a lack of low-cost and easily accessible diagnostic structures in countries where etiologic agents are present. Furthermore, initial clinical symptoms are common and shared with other endemic diseases such as malaria or typhoid fever. Current molecular diagnostic methods such as polymerase chain reaction require trained personnel and laboratory infrastructure, hindering diagnostics at the point of need, particularly in outbreak settings. Therefore, rapid diagnostic tests such as lateral flow can be broadly deployed and are typically well-suited to rapidly diagnose hemorrhagic fever viruses, such as Ebola virus. Early detection and control of Ebola outbreaks require simple, easy-to-use assays that can detect very low amount of virus in blood. Here, we developed and characterized an immunoassay test based on immunochromatography coupled to silver amplification technology to detect the secreted glycoprotein of EBOV. The glycoprotein is among the first viral proteins to be detected in blood. This strategy aims at identifying infected patients early following onset of symptoms by detecting low amount of sGP protein in blood samples. The limit of detection achieved by this sGP-targeted kit is 2.2 x 104 genome copies/ml in plasma as assayed in a monkey analytical cohort. Clinical performance evaluation showed a specificity of 100% and a sensitivity of 85.7% when evaluated with plasma samples from healthy controls and patients infected with Zaire Ebola virus from Macenta, Guinea. This rapid and accurate diagnostic test could therefore be used in endemic countries for early detection of infected individuals in point of care settings. Moreover, it could also support efficient clinical triage in hospitals or clinical centers and thus reducing transmission rates to prevent and better manage future severe outbreaks. Ebola virus disease is a severe disease caused by Ebola virus, a member of the filovirus family, which occurs in humans and other primates. Ebola is believed to be zoonotic, however the natural reservoir is unknown. Overlapping symptoms with other endemic diseases, such as malaria and cholera, make accurate diagnostic challenging. Outbreaks of Ebola have been widespread as the consequence of the absence of available rapid, sensitive, specific, robust, and affordable licensed diagnostic test in remote areas, where outbreaks usually start. Here we have established and validated a rapid diagnostic test, which is fast, sensitive, specific, efficient, affordable, and user-friendly. Its analytical characteristics make it suitable for clinical management during Ebola virus outbreaks in remote areas. Of interest, this rapid diagnostic test detects the presence of an early viral antigen, the secreted glycoprotein, found in blood of patients shortly after infection, suggesting that it could be used to identify infected patients shortly after onset of symptoms.
Collapse
Affiliation(s)
| | - Atsuhiko Wada
- FUJIFILM, Ushijima, Kaisei-machi, Ashigarakami-gun Kanagawa, Japan
| | | | | | | | - Moriba Povogui
- Centre de Recherche Et de Formation en Infectiologie de Guinée (CERFIG), République de Guinée
| | | | | | | | | | | | | | - Anne Bocquin
- INSERM Jean Mérieux BSL4 Laboratory, LYON, France
| | | | - Ismaël Béavogui
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | - Jean Hébélamou
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | - David Leuenberger
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | | | - Takeshi Yamamoto
- FUJIFILM, Ushijima, Kaisei-machi, Ashigarakami-gun Kanagawa, Japan
| | | | | | | |
Collapse
|
7
|
Fischer K, Camara A, Troupin C, Fehling SK, Strecker T, Groschup MH, Tordo N, Diederich S. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea. Transbound Emerg Dis 2019; 67:724-732. [PMID: 31627257 DOI: 10.1111/tbed.13391] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 09/18/2019] [Accepted: 10/10/2019] [Indexed: 02/06/2023]
Abstract
The genus Ebolavirus comprises several virus species with zoonotic potential and varying pathogenicity for humans. Ebolaviruses are considered to circulate in wildlife with occasional spillover events into the human population which then often leads to severe disease outbreaks. Several studies indicate a significant role of bats as reservoir hosts in the ebolavirus ecology. However, pigs from the Philippines have been found to be naturally infected with Reston virus (RESTV), an ebolavirus that is thought to only cause asymptomatic infections in humans. The recent report of ebolavirus-specific antibodies in pigs from Sierra Leone further supports natural infection of pigs with ebolaviruses. However, susceptibility of pigs to highly pathogenic Ebola virus (EBOV) was only shown under experimental settings and evidence for natural infection of pigs with EBOV is currently lacking. Between October and December 2017, we collected 308 serum samples from pigs in Guinea, West Africa, and tested for the presence of ebolavirus-specific antibodies with different serological assays. Besides reactivity to EBOV nucleoproteins in ELISA and Western blot for 19 (6.2%) and 13 (4.2%) samples, respectively, four sera recognized Sudan virus (SUDV) NP in Western blot. Furthermore, four samples specifically detected EBOV or SUDV glycoprotein (GP) in an indirect immunofluorescence assay under native conditions. Virus neutralization assay based on EBOV (Mayinga isolate) revealed five weakly neutralizing sera. The finding of (cross-) reactive and weakly neutralizing antibodies suggests the exposure of pigs from Guinea to ebolaviruses or ebola-like viruses with their pathogenicity as well as their zoonotic potential remaining unknown. Future studies should investigate whether pigs can act as an amplifying host for ebolaviruses and whether there is a risk for spillover events.
Collapse
Affiliation(s)
- Kerstin Fischer
- Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | | | | | - Sarah K Fehling
- Institute of Virology, Philipps University of Marburg, Marburg, Germany
| | - Thomas Strecker
- Institute of Virology, Philipps University of Marburg, Marburg, Germany
| | - Martin H Groschup
- Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | - Noel Tordo
- Institut Pasteur de Guineé, Conakry, Guinea
| | - Sandra Diederich
- Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| |
Collapse
|
8
|
Ogunro BN, Olugasa BO, Verschoor EJ, Olarinmoye AO, Theyse I, Niphuis H. Serological Detection of Ebola Virus Exposures in Native Non-human Primates of Southern Nigeria. J Epidemiol Glob Health 2019; 8:162-170. [PMID: 30864758 PMCID: PMC7377558 DOI: 10.2991/j.jegh.2018.05.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 05/14/2018] [Indexed: 01/08/2023] Open
Abstract
Ebola viruses (family: Filoviridae) are the cause of Ebola virus disease (EVD), a highly fatal illness characterised by haemorrhagic fever syndrome in both humans and non-human primates (NHPs). West Africa was the epicentre of the 2013-2015 EVD epidemic which caused the death of over 11,000 people, including eight casualties in southern Nigeria. Antibodies to filoviruses have been detected among NHPs in some countries, but there is no documented evidence of exposures to filoviruses among NHPs in Nigeria. From August 2015 to February 2017, a total of 142 serum samples were obtained from individual captive and wild animals, belonging to 11 NHP species, in southern Nigeria, and screened for species-specific antibodies to filoviruses belonging to the species; Zaire ebolavirus [Ebola virus (EBOV)], Sudan ebolavirus [Sudan virus (SUDV)], and Marburg marburgvirus [Ravn virus (RAVV)]-using a modified filovirus species-specific ELISA technique. Of the sera tested, 2.1% (3/142) were positive for antibodies to EBOV. The entire 142 sera were negative for SUDV or RAVV. These findings point to the existence of natural exposures of NHPs in southern Nigeria to EBOV. There is need to discourage, the uncontrolled hunting of NHPs in Nigeria for public health safety.
Collapse
Affiliation(s)
- B N Ogunro
- Veterinary Teaching Hospital, University of Ibadan, Ibadan, Oyo State, Nigeria.,Centre for Control and Prevention of Zoonoses, University of Ibadan, Ibadan, Oyo State, Nigeria.,Department of Veterinary Public Health and Preventive Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
| | - B O Olugasa
- Centre for Control and Prevention of Zoonoses, University of Ibadan, Ibadan, Oyo State, Nigeria.,Department of Veterinary Public Health and Preventive Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
| | - E J Verschoor
- Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
| | - A O Olarinmoye
- Centre for Control and Prevention of Zoonoses, University of Ibadan, Ibadan, Oyo State, Nigeria.,College of Dentistry Research Center (CDRC), King Saud University, Riyadh, Saudi Arabia
| | - I Theyse
- Center for Education, Research and Conservation of Primates and Nature, Calabar, Cross River State, Nigeria
| | - H Niphuis
- Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
| |
Collapse
|
9
|
Fischer K, Jabaty J, Suluku R, Strecker T, Groseth A, Fehling SK, Balkema-Buschmann A, Koroma B, Schmidt KM, Atherstone C, Weingartl HM, Mettenleiter TC, Groschup MH, Hoenen T, Diederich S. Serological Evidence for the Circulation of Ebolaviruses in Pigs From Sierra Leone. J Infect Dis 2019; 218:S305-S311. [PMID: 29982580 DOI: 10.1093/infdis/jiy330] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Many human ebolavirus outbreaks have been linked to contact with wildlife including nonhuman primates and bats, which are assumed to serve as host species. However, it is largely unknown to what extent other animal species, particularly livestock, are involved in the transmission cycle or act as additional hosts for filoviruses. Pigs were identified as a susceptible host for Reston virus with subsequent transmission to humans reported in the Philippines. To date, there is no evidence of natural Ebola virus (EBOV) infection in pigs, although pigs were shown to be susceptible to EBOV infection under experimental settings. To investigate the potential role of pigs in the ecology of EBOV, we analyzed 400 porcine serum samples from Sierra Leone for the presence of ebolavirus-specific antibodies. Three samples reacted with ebolavirus nucleoproteins but had no neutralizing antibodies. Our results (1) suggest the circulation of ebolaviruses in swine in Sierra Leone that are antigenically related but not identical to EBOV and (2) could represent undiscovered ebolaviruses with unknown pathogenic and/or zoonotic potential.
Collapse
Affiliation(s)
- Kerstin Fischer
- Friedrich-Loeffler-Institut Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | - Juliet Jabaty
- Sierra Leone Agricultural Research Institute, Teko Livestock Research Centre, Sierra Leone
| | - Roland Suluku
- Njala University, Animal Science, Serology and Molecular Laboratory, Sierra Leone
| | - Thomas Strecker
- Institute of Virology, Philipps University of Marburg, Germany
| | - Allison Groseth
- Junior Research Group Arenavirus Biology, Greifswald - Insel Riems, Germany
| | - Sarah K Fehling
- Institute of Virology, Philipps University of Marburg, Germany
| | - Anne Balkema-Buschmann
- Friedrich-Loeffler-Institut Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | - Bashiru Koroma
- Njala University, Animal Science, Serology and Molecular Laboratory, Sierra Leone
| | - Kristina M Schmidt
- Friedrich-Loeffler-Institut Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | - Christine Atherstone
- Sydney School of Veterinary Science, University of Sydney, Australia.,International Livestock Research Institute, Kampala, Uganda
| | - Hana M Weingartl
- National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Manitoba, Canada
| | | | - Martin H Groschup
- Friedrich-Loeffler-Institut Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| | - Thomas Hoenen
- Institute of Molecular Virology and Cell Biology, Greifswald - Insel Riems, Germany
| | - Sandra Diederich
- Friedrich-Loeffler-Institut Institute of Novel and Emerging Infectious Diseases, Greifswald - Insel Riems, Germany
| |
Collapse
|
10
|
Timothy JWS, Hall Y, Akoi-Boré J, Diallo B, Tipton TRW, Bower H, Strecker T, Glynn JR, Carroll MW. Early transmission and case fatality of Ebola virus at the index site of the 2013-16 west African Ebola outbreak: a cross-sectional seroprevalence survey. THE LANCET. INFECTIOUS DISEASES 2019; 19:429-438. [PMID: 30799252 PMCID: PMC6437313 DOI: 10.1016/s1473-3099(18)30791-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 11/15/2018] [Accepted: 12/06/2018] [Indexed: 12/12/2022]
Abstract
BACKGROUND To date, epidemiological studies at the index site of the 2013-16 west African Ebola outbreak in Meliandou, Guinea, have been restricted in their scope. We aimed to determine the occurrence of previously undocumented Ebola virus disease (EVD) cases and infections, and to reconstruct transmission events. METHODS This cross-sectional seroprevalence survey of the adult population of Meliandou used a highly specific oral fluid test and detailed interviews of all households in the village and key informants. Each household was interviewed, with all members prompted to describe the events of the outbreak, any illness within the household, and possible contact with suspected cases. Information for deceased individuals was provided by relatives living in the same household. Symptoms were based on Ebola virus Makona variant EVD case definitions (focusing on fever, vomiting, and diarrhoea). For antibody testing, we used an Ebola virus glycoprotein IgG capture enzyme immunoassay developed from a previously validated assay. A maximum exposure level was assigned to every participant using a predetermined scale. We used a generalised linear model (logit function) to estimate odds ratios for the association of sociodemographic variables and exposure level with Ebola virus infection. We adjusted estimates for age and maximum exposure, as appropriate. FINDINGS Between June 22, and July 9, 2017, we enrolled 237 participants from 27 households in Meliandou. Two households refused to participate and one was absent. All adults in participating households who were present for the interview provided an oral fluid swab for testing, of which 224 were suitable for analysis. In addition to the 11 EVD deaths described previously, on the basis of clinical description and oral fluid testing, we found two probable EVD deaths and eight previously unrecognised anti-Ebola virus IgG-positive survivors, including one who had mild symptoms and one who was asymptomatic, resulting in a case fatality of 55·6% (95% CI 30·8-78·5) for adults. Health-care work (adjusted odds ratio 6·64, 1·54-28·56; p=0·001) and level of exposure (odds ratio adjusted for linear trend across five levels 2·79, 1·59-4·883; p<0·0001) were independent risk factors for infection. INTERPRETATION Ebola virus infection was more widespread in this spillover population than previously recognised (21 vs 11 cases). We show the first serological evidence of survivors in this population (eight anti-Ebola virus IgG seropositive) and report a case fatality lower than previously reported (55·6% vs 100% in adults). These data show the high community coverage achievable by using a non-invasive test and, by accurately documenting the beginnings of the west African Ebola virus outbreak, reveal important insight into transmission dynamics and risk factors that underpin Ebola virus spillover events. FUNDING US Food and Drug Administration, Wellcome Trust, and German Research Council.
Collapse
Affiliation(s)
| | - Yper Hall
- Research and Development Institute, National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - Joseph Akoi-Boré
- Public Health England/Tropical Medicine Institute Berlin Reference Laboratory, Guéckédou, Guinea
| | - Boubacar Diallo
- World Health Organization, Regional Office for Africa, Brazzaville, Republic of Congo
| | - Thomas R W Tipton
- Research and Development Institute, National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - Hilary Bower
- London School of Hygiene & Tropical Medicine, London, UK
| | - Thomas Strecker
- Institute of Virology, Philipps University, Marburg, Germany
| | - Judith R Glynn
- London School of Hygiene & Tropical Medicine, London, UK
| | - Miles W Carroll
- Research and Development Institute, National Infection Service, Public Health England, Porton Down, Salisbury, UK
| |
Collapse
|
11
|
Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer D, Nicholson BP, Williams R, Mossoko M, Ilunga-Kebela B, Wasiswa J, Okitolonda-Wemakoy E, Alfonso VH, Steffen I, Muyembe-Tamfum JJ, Simmons G, Rimoin AW. Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo. J Infect Dis 2019; 219:517-525. [PMID: 30239838 PMCID: PMC6350949 DOI: 10.1093/infdis/jiy499] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Accepted: 08/18/2018] [Indexed: 12/17/2022] Open
Abstract
Healthcare settings have played a major role in propagation of Ebola virus (EBOV) outbreaks. Healthcare workers (HCWs) have elevated risk of contact with EBOV-infected patients, particularly if safety precautions are not rigorously practiced. We conducted a serosurvey to determine seroprevalence against multiple EBOV antigens among HCWs of Boende Health Zone, Democratic Republic of the Congo, the site of a 2014 EBOV outbreak. Interviews and specimens were collected from 565 consenting HCWs. Overall, 234 (41.4%) of enrolled HCWs were reactive to at least 1 EBOV protein: 159 (28.1%) were seroreactive for anti-glycoprotein immunoglobulin G (IgG), 89 (15.8%) were seroreactive for anti-nucleoprotein IgG, and 54 (9.5%) were VP40 positive. Additionally, sera from 16 (2.8%) HCWs demonstrated neutralization capacity. These data demonstrate that a significant proportion of HCWs have the ability to neutralize virus, despite never having developed Ebola virus disease symptoms, highlighting an important and poorly documented aspect of EBOV infection and progression.
Collapse
Affiliation(s)
- Nicole A Hoff
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - Patrick Mukadi
- Institut National de Recherche Biomédicale, Washington, District of Columbia
- Faculté de Médecine, Université de Kinshasa, Democratic Republic of the Congo (DRC), Washington, District of Columbia
| | - Reena H Doshi
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - Matthew S Bramble
- Department of Genetic Medicine Research, Children’s Research Institute, Children’s National Medical Center, Washington, District of Columbia
| | - Kai Lu
- Blood Systems Research Institute, San Francisco
- Department of Laboratory Medicine, University of California, San Francisco
| | - Adva Gadoth
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - Cyrus Sinai
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - D’Andre Spencer
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - Bradley P Nicholson
- Molecular Epidemiology Research Laboratory, Veterans Affairs Medical Center, Durham, North Carolina
| | | | - Matthias Mossoko
- Direction de lutte contre la Maladie, Ministère de la Santé Publique
| | | | - Joseph Wasiswa
- University of California, Los Angeles-DRC Research Program
- Direction de lutte contre la Maladie, Ministère de la Santé Publique
| | | | - Vivian H Alfonso
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| | - Imke Steffen
- Blood Systems Research Institute, San Francisco
- Department of Laboratory Medicine, University of California, San Francisco
| | - Jean-Jacques Muyembe-Tamfum
- Institut National de Recherche Biomédicale, Washington, District of Columbia
- Faculté de Médecine, Université de Kinshasa, Democratic Republic of the Congo (DRC), Washington, District of Columbia
| | - Graham Simmons
- Blood Systems Research Institute, San Francisco
- Department of Laboratory Medicine, University of California, San Francisco
| | - Anne W Rimoin
- Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
| |
Collapse
|
12
|
Filovirus – Auslöser von hämorrhagischem Fieber. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61:894-907. [DOI: 10.1007/s00103-018-2757-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Serological Detection of Ebola Virus Exposures in Native Non-human Primates of Southern Nigeria. J Epidemiol Glob Health 2018. [DOI: 10.1016/j.jegh.2018.05.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|